Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
04 06 2020
Historique:
received: 26 09 2019
accepted: 23 04 2020
pubmed: 6 5 2020
medline: 19 5 2021
entrez: 6 5 2020
Statut: epublish

Résumé

Loss of melanocytes is the pathological hallmark of vitiligo, a chronic inflammatory skin depigmenting disorder induced by exaggerated immune response, including autoreactive CD8 T cells producing high levels of type 1 cytokines. However, the interplay between this inflammatory response and melanocyte disappearance remains to be fully characterized. Here, we demonstrate that vitiligo skin contains a significant proportion of suprabasal melanocytes, associated with disruption of E-cadherin expression, a major protein involved in melanocyte adhesion. This phenomenon is also observed in lesional psoriatic skin. Importantly, apoptotic melanocytes were mainly observed once cells were detached from the basal layer of the epidermis, suggesting that additional mechanism(s) could be involved in melanocyte loss. The type 1 cytokines IFN-γ and TNF-α induce melanocyte detachment through E-cadherin disruption and the release of its soluble form, partly due to MMP-9. The levels of MMP-9 are increased in the skin and sera of patients with vitiligo, and MMP-9 is produced by keratinocytes in response to IFN-γ and TNF-α. Inhibition of MMP-9 or the JAK/STAT signaling pathway prevents melanocyte detachment in vitro and in vivo. Therefore, stabilization of melanocytes in the basal layer of the epidermis by preventing E-cadherin disruption appears promising for the prevention of depigmentation occurring in vitiligo and during chronic skin inflammation.

Identifiants

pubmed: 32369451
pii: 133772
doi: 10.1172/jci.insight.133772
pmc: PMC7308056
doi:
pii:

Substances chimiques

Cadherins 0
Cdh1 protein, mouse 0
IFNG protein, human 0
IFNG protein, mouse 0
Tumor Necrosis Factor-alpha 0
Interferon-gamma 82115-62-6
MMP9 protein, human EC 3.4.24.35
Matrix Metalloproteinase 9 EC 3.4.24.35
Mmp9 protein, mouse EC 3.4.24.35

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Am Acad Dermatol. 2020 Feb 14;:
pubmed: 32068039
Cancer Res. 2012 Jun 15;72(12):2917-23
pubmed: 22659456
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2301-6
pubmed: 24474804
Sci Rep. 2016 Nov 08;6:36336
pubmed: 27824116
Nat Rev Immunol. 2013 Sep;13(9):649-65
pubmed: 23969736
J Clin Immunol. 2006 Jul;26(4):299-307
pubmed: 16652230
Am J Clin Dermatol. 2013 Oct;14(5):343-50
pubmed: 23912226
J Am Acad Dermatol. 2018 Jun;78(6):1205-1207.e1
pubmed: 29438765
Crit Rev Biochem Mol Biol. 2013 May-Jun;48(3):222-72
pubmed: 23547785
J Invest Dermatol. 2009 Sep;129(9):2220-32
pubmed: 19242513
Pigment Cell Res. 2003 Aug;16(4):322-32
pubmed: 12859615
Immunity. 2017 Feb 21;46(2):287-300
pubmed: 28214226
Acta Derm Venereol. 2015 Jul;95(6):664-70
pubmed: 25721262
Curr Protoc Immunol. 2019 Feb;124(1):e63
pubmed: 30253067
Exp Dermatol. 2019 Jun;28(6):662-666
pubmed: 30536790
Clin Rev Allergy Immunol. 2018 Feb;54(1):52-67
pubmed: 28685247
J Invest Dermatol. 2009 May;129(5):1088-99
pubmed: 19242512
Sci Transl Med. 2018 Jul 18;10(450):
pubmed: 30021889
Br J Dermatol. 2011 Aug;165(2):285-91
pubmed: 21428970
J Invest Dermatol. 2018 Feb;138(2):355-364
pubmed: 28927891
J Am Acad Dermatol. 2017 Oct;77(4):675-682.e1
pubmed: 28823882
Nat Rev Mol Cell Biol. 2005 Aug;6(8):622-34
pubmed: 16025097
Nat Commun. 2019 May 16;10(1):2178
pubmed: 31097717
FASEB J. 2007 Feb;21(2):356-65
pubmed: 17158965
J Invest Dermatol. 1991 Feb;96(2):180-5
pubmed: 1899443
J Immunol. 2019 Jul 1;203(1):11-19
pubmed: 31209143
BMC Immunol. 2009 Mar 19;10:15
pubmed: 19298660
Nat Rev Drug Discov. 2007 Jun;6(6):480-98
pubmed: 17541420
G Ital Dermatol Venereol. 2016 Feb;151(1):44-54
pubmed: 26512930
Pigment Cell Res. 2002 Feb;15(1):41-8
pubmed: 11837455
Med Res Rev. 2017 Jul;37(4):907-935
pubmed: 28029168
Lab Invest. 2000 Aug;80(8):1299-309
pubmed: 10950121
J Immunol. 2010 Feb 15;184(4):1909-17
pubmed: 20083666
Nat Rev Dis Primers. 2015 Jun 04;1:15011
pubmed: 27189851
Br J Dermatol. 2017 Nov;177(5):1367-1375
pubmed: 28380264
J Cell Sci. 1994 Apr;107 ( Pt 4):983-92
pubmed: 8056851
J Invest Dermatol. 2012 Jul;132(7):1869-76
pubmed: 22297636
J Allergy Clin Immunol. 2017 Sep;140(3):645-653
pubmed: 28887948
Nat Rev Immunol. 2004 Aug;4(8):617-29
pubmed: 15286728
Autoimmun Rev. 2011 Oct;10(12):762-5
pubmed: 21334464
Sci Transl Med. 2014 Feb 12;6(223):223ra23
pubmed: 24523323
JAMA Dermatol. 2015 Oct;151(10):1110-2
pubmed: 26107994
J Exp Med. 2015 Dec 14;212(13):2203-12
pubmed: 26621454
Am J Respir Cell Mol Biol. 2011 May;44(5):700-8
pubmed: 20639459
J Am Acad Dermatol. 2017 Jun;76(6):1054-1060.e1
pubmed: 28390737
J Invest Dermatol. 2013 Dec;133(12):2741-2752
pubmed: 23732752
Clin Exp Dermatol. 2011 Oct;36(7):708-14
pubmed: 21671990
J Am Acad Dermatol. 2015 Aug;73(2):272-5
pubmed: 26054430
J Am Acad Dermatol. 2017 May;76(5):856-862
pubmed: 28245942
Br J Dermatol. 1997 Aug;137(2):171-8
pubmed: 9292062
Dermatology. 2016;232(4):425-30
pubmed: 27497917
Pigment Cell Res. 2007 Feb;20(1):27-35
pubmed: 17250545
Lab Invest. 2003 May;83(5):683-95
pubmed: 12746478
Mol Med Rep. 2013 Jan;7(1):237-41
pubmed: 23042234
J Invest Dermatol. 2015 Jul;135(7):1810-1819
pubmed: 25634357
Oncogene. 1999 Feb 25;18(8):1553-9
pubmed: 10102625
Pigment Cell Res. 2002 Dec;15(6):426-32
pubmed: 12453184

Auteurs

Nesrine Boukhedouni (N)

INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC), Immunodermatology ATIP-AVENIR, University of Bordeaux, FHU ACRONIM, Bordeaux, France.

Christina Martins (C)

INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC), Immunodermatology ATIP-AVENIR, University of Bordeaux, FHU ACRONIM, Bordeaux, France.

Anne-Sophie Darrigade (AS)

INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC), Immunodermatology ATIP-AVENIR, University of Bordeaux, FHU ACRONIM, Bordeaux, France.
Department of Dermatology and Pediatric Dermatology and National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Bordeaux, France.

Claire Drullion (C)

INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC), Immunodermatology ATIP-AVENIR, University of Bordeaux, FHU ACRONIM, Bordeaux, France.

Jérôme Rambert (J)

AquiDerm, University of Bordeaux, Bordeaux, France.

Christine Barrault (C)

Bioalternatives, Gençay, France.

Julien Garnier (J)

Bioalternatives, Gençay, France.

Clément Jacquemin (C)

INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC), Immunodermatology ATIP-AVENIR, University of Bordeaux, FHU ACRONIM, Bordeaux, France.

Denis Thiolat (D)

INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC), Immunodermatology ATIP-AVENIR, University of Bordeaux, FHU ACRONIM, Bordeaux, France.

Fabienne Lucchese (F)

INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC), Immunodermatology ATIP-AVENIR, University of Bordeaux, FHU ACRONIM, Bordeaux, France.

Franck Morel (F)

Laboratoire Inflammation, Tissus Epithéliaux et Cytokines, University of Poitiers, Poitiers, France.

Khaled Ezzedine (K)

Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor, Créteil, France.

Alain Taieb (A)

Department of Dermatology and Pediatric Dermatology and National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Bordeaux, France.

François-Xavier Bernard (FX)

Bioalternatives, Gençay, France.

Julien Seneschal (J)

INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC), Immunodermatology ATIP-AVENIR, University of Bordeaux, FHU ACRONIM, Bordeaux, France.
Department of Dermatology and Pediatric Dermatology and National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Bordeaux, France.

Katia Boniface (K)

INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC), Immunodermatology ATIP-AVENIR, University of Bordeaux, FHU ACRONIM, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH